Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

User Fees: Should US FDA Incur Penalties For Missed Deadlines?

Mar 27 2017

• By Derrick Gingery

US-Money-and-Pills_V2_1200x675

Related Content

FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015

Apr 25 2016

Do FDA Submission, Approval Declines Outside Cancer Signal Future Treatment Gaps?

Dec 15 2016

PDUFA V Reviews Are ‘Best Ever’ For Some Sponsors, Maybe Not FDA

Apr 06 2015

Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan

Sep 28 2016

PDUFA Fees Forced Down For FY 2017 Due To Refund Provision

Jul 27 2016

What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down

Nov 08 2016

Senate adopts user fee bill in rare 'Kumbaya' moment

May 25 2012

Trump's Budget Outline Threatens User Fee Agreements

Mar 17 2017

The Freeze Thaws: US FDA Allowed To Hire Staff For Cures, User Fee Activity

Mar 23 2017

100% User Fees For US FDA? Trump Budget Revives Important Issue For Industry – But Not This Year

Mar 24 2017

US FDA Headquarters Parking Problem May Create Security Risk

Jan 06 2017

Burr Warns User Fee Renewal Could Be Difficult Without Performance Measure Improvements

Jul 28 2011

FDA Construction Plans Need 'Innovative Financing Options'

Jun 20 2016

Additional Topics

United States Approvals FDA Regulation Drug Review Review Pathway BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window